pharma · Diabetes Mellitus · Hemophilia A
Takeda
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 1993
- Employees
- 1,617
- Programs
- 1179
- Drugs
- 359
- Patents
- 1436
Quick answer
Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179 clinical program(s), 34 drug profile(s), and 1436 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (393), phase 2 (335), phase 1 (276).
Company snapshot
Takeda maintains 1179 tracked programs across Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus, Ulcerative Colitis, Hereditary Angioedema (HAE), Primary Immunodeficiency Diseases (PID), Multiple Myeloma, Schizophrenia, Type 2 Diabetes, Colitis, Ulcerative. Momentum score: 35/100 (30-day delta: n/a). Public registry data covers pipeline phase, clinical trials
- 42 approved product(s) across US/EU regulatory metadata.
- 1179 active pipeline program(s) linked via ClinicalTrials.gov.
- 1436 US patent(s) indexed to this assignee profile.
Public regulatory, clinical, patent, and corporate records for Takeda. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes
- deal
Analysis of BMS-Hengrui's $15B Deal and Its Implications
- approval
Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More
- approval
Layoff Tracker: Takeda and Novartis Restructure Amid Industry Changes
- approval
Layoff Tracker: Takeda and Novartis Restructuring Impact
- approval
Takeda and Novartis Layoffs: Implications for Pharma Industry
- deal
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
- deal
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Recent coverage
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Takeda’s TYK2 inhibitor zasocitinib outperformed Bristol Myers Squibb’s Sotyktu in a head-to-head plaque psoriasis trial. The result strengthens Takeda’s dermatology story and gives BD teams and investors a clearer read on the program’s competitive position.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
Takeda and Novartis Layoffs: Implications for Pharma Industry
Takeda announces a reduction of 4,500 jobs while Novartis lays off biomedical research staff. This article explores the implications for the pharma sector.
Takeda's $885M Verdict: Implications for Pharma Business Strategies
Takeda faces an $885M verdict in a pay-for-delay antitrust case, raising significant questions for pharmaceutical business strategies and market dynamics.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- approved
Momentum
Proprietary activity score for Takeda.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Takeda.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Takeda?
-
Is Takeda publicly traded?
-
What drugs does Takeda develop or market?
-
What are the latest developments for Takeda?
-
What therapeutic areas does Takeda focus on?
Full intelligence profile
Registry synthesis
Grounded overview from trials, patents, coverage, and catalysts.
Takeda maintains 1179 tracked programs across Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus, Ulcerative Colitis, Hereditary Angioedema (HAE), Primary Immunodeficiency Diseases (PID), Multiple Myeloma, Schizophrenia, Type 2 Diabetes, Colitis, Ulcerative. Momentum score: 35/100 (30-day delta: n/a).
Public registry data covers pipeline phase, clinical trials, patents, SEC filings, and Nova editorial coverage. HQ: Cambridge USA. Ticker: TAK.
Pipeline programs
Vedolizumab — phase phase_3, status completed. Indication: Colitis, Ulcerative. Next milestone: not disclosed (TBD).
Vedolizumab — phase phase_3, status completed. Indication: Ulcerative Colitis. Next milestone: not disclosed (TBD).
TAK-816+ DPT-TAKEDA — phase phase_3, status completed. Indication: Immunization. Next milestone: not disclosed (TBD).
Vedolizumab 300 mg IV — phase phase_3, status completed. Indication: Colitis, Ulcerative. Next milestone: not disclosed (TBD).
Vedolizumab SC 108 mg — phase phase_3, status completed. Indication: Crohn's Disease. Next milestone: not disclosed (TBD).
Vedolizumab SC — phase phase_3, status completed. Indication: Colitis, Ulcerative. Next milestone: not disclosed (TBD).
SPD476-302 — phase phase_3, status completed. Indication: Ulcerative Colitis. Next milestone: not disclosed (TBD).
TAK-771 — phase phase_3, status completed. Indication: Primary Immunodeficiency Diseases (PID). Next milestone: not disclosed (TBD).
Fasiglifam (TAK-875) — phase phase_3, status terminated. Indication: Diabetes Mellitus, Type 2. Next milestone: not disclosed (TBD).
Alogliptin — phase phase_3, status completed. Indication: Diabetes Mellitus. Next milestone: not disclosed (TBD).
Vedolizumab IV — phase phase_3, status active. Indication: Ulcerative Colitis. Next milestone: not disclosed (TBD).
Maribavir — phase phase_3, status completed. Indication: Cytomegalovirus (CMV). Next milestone: not disclosed (TBD).
Recent Nova coverage
Nova coverage: Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test (2026-06-11).
Nova coverage: Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss (2026-05-22).
Nova coverage: Takeda and Novartis Layoffs: Implications for Pharma Industry (2026-05-21).
Nova coverage: Takeda's $885M Verdict: Implications for Pharma Business Strategies (2026-05-20).
Nova coverage: Layoff Tracker: Takeda and Novartis Restructuring Impact (2026-05-20).
Nova coverage: Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More (2026-05-19).
Nova coverage: Layoff Tracker: Takeda and Novartis Restructure Amid Industry Changes (2026-05-19).
Nova coverage: Analysis of BMS-Hengrui's $15B Deal and Its Implications (2026-05-18).
Registry facts
Registry profile: founded 1993; employees 1617; market cap n/a; revenue n/a; LEI n/a; CIK 0001395064.
Company type: pharma; public/private: public. Data quality score: 0.864.
Catalyst calendar
Catalyst: Fierce Pharma Asia: Major Developments in Oncology and Workforce Changes — type approval, date 2026-05-17.
Catalyst: Analysis of BMS-Hengrui's $15B Deal and Its Implications — type deal, date 2026-05-18.
Catalyst: Fierce Pharma Asia: BMS-Hengrui's $15B Deal and More — type approval, date 2026-05-19.
Catalyst: Layoff Tracker: Takeda and Novartis Restructure Amid Industry Changes — type approval, date 2026-05-19.
Catalyst: Layoff Tracker: Takeda and Novartis Restructuring Impact — type approval, date 2026-05-20.
Catalyst: Takeda and Novartis Layoffs: Implications for Pharma Industry — type approval, date 2026-05-21.
Catalyst: Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss — type deal, date 2026-05-22.
Catalyst: Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test — type deal, date 2026-06-11.
Competitive peers
Peer: IONIS PHARMACEUTICALS (overlap score 50.0).
Peer: Eli Lilly and (overlap score 50.0).
Peer: Teva Pharma (overlap score 40.0).
Peer: AstraZeneca (overlap score 40.0).
Peer: AbbVie Deutschland GmbH (overlap score 40.0).
Peer: First People's Hospital (overlap score 40.0).
Peer: Boehringer Ingelheim (overlap score 40.0).
Peer: Lakefront Biotherapeutics NV (overlap score 39.8).
Competitive positioning reflects therapeutic-area overlap with peer sponsors and recent catalyst activity from trials, regulatory actions, and congress presentations. Data is assembled from ClinicalTrials.gov, SEC EDGAR, openFDA, and NovaPharmaNews articles — not third-party wire republication.
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.